Depolymerase improves gentamicin efficacy during  induced murine infection by unknown
RESEARCH ARTICLE Open Access
Depolymerase improves gentamicin efficacy
during Klebsiella pneumoniae induced murine
infection
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Abstract
Background: Presence of capsule enhances the virulence of bacteria that cause pneumonia, meningitis, cystic
fibrosis, dental caries, periodontitis. Capsule is an important virulence factor for Klebsiella pneumoniae and infections
due to this pathogen have been associated with high mortality rates. In the present study, use of an Aeromonas
punctata derived capsule depolymerase against K. pneumoniae, to reinstate the efficacy of gentamicin during
pneumonia and septicemia was investigated.
Methods: Depolymerase was administered in mice intraperitoneally (50 μg) alone as well in combination with
gentamicin (1.5 mg/kg), 24 h post infection during acute lung infection and 6 h later during septicemia. Bacterial
load, neutrophil infiltration and cytokine levels were estimated. The immunogenicity of protein was also studied.
Results: In comparison to groups treated with gentamicin alone, combination treatment with depolymerase and
gentamicin significantly reduced (P < 0.01) bacterial titer in the lungs, liver, kidney, spleen and blood of
experimental animals. Highly significant reduction in neutrophil infiltration and levels of pro-inflammatory and
anti-inflammatory cytokines was also observed. This indicated an efficient capsule removal by the enzyme, that
improved gentamicin efficacy in vivo. Although the enzyme was found to be immunogenic, but no significant
reduction in treatment efficacy was observed in the preimmunized as well as naïve mice. In addition, as confirmed
through flow cytometry, the hyperimmune sera raised against the enzyme did not neutralize its activity.
Conclusion: The results confirm that administration of enzyme ‘depolymerase’ along with gentamicin not only
checked the virulence of K. pneumoniae in vivo but it also increased its susceptibility to gentamicin at a lower
concentration. Such a strategy would help to avoid exposure to higher concentration of gentamicin. Moreover, since
this decapsulating protein does not possess a lytic activity therefore there would be no chances of development of
bacterial resistance against it. Therefore, it should be studied further for its successful inclusion in our prophylactic/
therapeutic regimes.
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Background
Capsular polysaccharide (CPS) is a discrete layer tightly
bound to the bacterial cell wall. It is a major virulence
determinant in pathogens like Streptococcus pneumoniae,
Neisseria meningitidis, Haemophilus influenzae, Klebsiella
pneumoniae, Escherichia coli, Cryptococcus neoformans etc.
[1-4]. It mediates adherence, protects bacteria against
dessication, bacteriophages and immune response [5].
Strains possessing capsules can evade immune responses
by several mechanisms. Firstly, their hydrophilic nature
and net negative charge repel the negatively charged sur-
face of phagocytes thereby diminishing bacterial removal
through phagocytosis [6]. Secondly, capsular polysaccha-
rides mask the pathogen-associated molecular patterns
(PAMPs) that are recognised by Toll-like receptors (TLRs)
thereby preventing activation of immune response [7,8].
Thirdly, presence of capsule may cause deficient binding,
degradation or masking of complement components [9].
In addition, encapsulated bacteria might be protected
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from various antimicrobial peptides (APs) present in
mucosal surfaces [10].
Klebsiella pneumoniae is a common cause of nosocomial
infections including urinary tract, respiratory, wound infec-
tions, bacteremia, septicemia, pyogenic liver abscess etc.
[11]. K. pneumoniae CPS is antiphagocytic, mediates serum
resistance and induces cytotoxicity during infection of lung
epithelial cells. It also helps in bacterial colonization and
biofilm formation at infection sites [12]. Of the 78 chem-
ically distinct capsular types of K. pneumoniae, K1 and K2
are the most virulent. They have been frequently isolated
from patients with bacteremia and respiratory tract infec-
tions [13,14]. Aminoglycosides and fluoroquinolones have
been widely used for restricting the growth of members of
Enterobacteriaceae family. Antibiotics might kill the free-
floating bacteria in vivo but fail to eradicate bacterial cells
embedded in a biofilm [15]. The, bacterial CPS is known to
interfere with the penetration of many antibiotics, leading
to exposure of bacteria to sub-MIC concentrations, that
increases the risk of resistance [16]. These mounting
concerns underscore the need for an effective alterna-
tive treatment strategy for infections.
CPS is an excellent target for compounds aimed at
replacing or supplementing antibiotic treatment for
microbial infections. CPS synthesis can be blocked
by deleting or downregulating the genes for capsule
biosynthesis [5]. The therapeutic interventions include
‘capsule-stripping’ by using naturally occurring or engi-
neered bacteria or bacteriophages that secrete pathogen-
specific CPS-depolymerizing enzymes like lyase, glycosidase,
endosialidase, polyglutamic acid depolymerase [5].
No report is available on the in vivo use of an enzyme
derived from unrelated genera capable of decapsulating
K. pneumoniae. In the present study, a Aeromonas punc-
tata derived depolymerase was used to alter the severity
of infection during K. pneumoniae induced pneumonia
and septicemia. Enzyme treatment of this kind can
provide several advantages during bacterial infections.
They attenuate the virulence of denuded pathogen and
improve its susceptibility to immune defences. They can
also be useful as adjuncts to antibiotics for an early re-
covery from infection. Since they are not directly bacteri-
cidal they do not allow generation of resistant mutants




Klebsiella pneumoniae B5055 (O1:K2), obtained from Dr
Mathia Trautmann, Department of Medical Microbiol-
ogy and Hygiene, University of Ulm, Germany, stored in
our laboratory in 60% glycerol at −80°C and maintained
on nutrient agar slants at 4°C, was used in the study.
Gentamicin (Himedia, India) stock solution (2 mg/ml)
was prepared in sterile distilled water according to the
method of Andrews [18]. It was administered to mice at
a final concentration of 1.5 mg/kg body wt. throughout
the study.
Enzyme
Bacterial depolymerase isolated from A. punctata (Gen-
Bank: KF158411), capable of acting on the K2 capsular
polysaccharide of K. pneumoniae B5055 (composed of
glucose, mannose and glucuronic acid) was used. Pro-
duction of bacterial depolymerase was carried out by
cultivating A. punctata in a statistically optimized media
as standardized in our laboratory [19]. Cell free super-
natant containing enzyme was obtained and purified by
anion exchange (DEAE) followed by gel filtration chro-
matography (Sephadex G100). The enzyme was purified
to homogeneity and used at a concentration of 50 μg
throughout the study. [Decapsulation of K. pneumoniae
B5055 after treatment with A. punctata derived depoly-
merase is depicted in Additional file 1].
Animals
Pathogen-free BALB/c mice of either sex, 6–8 weeks old,
weighing 20–25 g were procured from the central animal
house of Panjab University, Chandigarh, India. Animals
were kept in clear polypropylene cages and fed on a stand-
ard antibiotic-free diet (Hindustan Lever Products, Kolkata,
India) and water ad libitum. The temperature ranged be-
tween 18 and 22°C and relative humidity was between 55
and 65%.
Ethics statement: The study was conducted after obtain-
ing approval from the Institutional Animal ethics commit-
tee of Panjab University [Approval ID: IAEC/346-356]. All
experiment protocols were performed in accordance with
the guidelines of Committee for the Purpose of Control
and Supervision of Experiments on Animals (CPCSEA),
Government of India. All efforts were made to minimize
the suffering of animals.
[Note: Bacterial doses corresponding to 102-108 CFU/ml
were tried for inducing acute lung infection after intrana-
sal administration or septicemia after intraperitoneal ad-
ministration. The dose which gave 100% infection without
causing any mortality was chosen for this work. (i.e.
104 CFU/50 μl for i.n infection and 102 CFU/100 μl for
systemic infection by i.p route)].
Treatment efficacy in acute lung infection model
K. pneumoniae B5055 was cultivated for 24 h at 37°C in
nutrient broth. Next day, cells were pelleted and washed
twice with normal saline (0.85% NaCl). Bacterial suspen-
sion prepared in saline was adjusted to achieve a cell
density corresponding to 2 × 105 CFU/ml (O.D = 0.03).
Acute lung infection was induced in mice following the
method of Held et al. [20] modified by Yadav et al. [21].
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Intranasal instillation of 104 CFU of K. pneumoniae
B5055 in a volume of 50 μl was performed by holding
the mice in an upright position without any anaesthesia.
Infected mice were then randomly divided into four
groups with each group comprising 20 animals. Different
groups were given one of the following treatments:
Group 1 (control): Mice infected with K. pneumoniae
B5055, given normal saline intraperitoneally.
Group 2: Mice infected with K. pneumoniae B5055
followed by intraperitoneal administration of gentamicin
(1.5 mg/kg/daily), initiated 24 h post infection.
Group 3: Mice infected with K. pneumoniae B5055
followed by intraperitoneal administration of the A. punc-
tata derived depolymerase (50 μg), 24 h post infection.
Group 4: Mice infected with K. pneumoniae B5055
followed by intraperitoneal administration of depolymer-
ase (50 μg) as well as gentamicin (1.5 mg/kg, daily), 24 h
post infection.
[Note: Optimal dose of A. punctata derived depolymer-
ase to be used was chosen based on the results of prelim-
inary experiments carried out using different doses, 25 μg,
50 μg and 75 μg. Dose giving maximum log reduction
after in vivo administration was thus selected].
Animals were sacrificed on different days [1-3,5,7]
post-infection by cervical dislocation and lungs were re-
moved aseptically. Bacterial load, pro-inflammatory and
anti-inflammatory cytokine levels were estimated in lung
tissue homogenates while histopathological examination
was carried out for the intact lung tissue.
Effect on systemic infection
Systemic infection was induced in mice by intraperitoneal
administration of 102 CFU of overnight grown and washed
K. pneumoniae B5055 in a volume of 0.1 ml. Thereafter,
mice were divided into the following 4 groups with each
group comprising of 10 animals:
Group 1 (control): Mice infected with K. pneumoniae
B5055 and given normal saline intraperitoneally, 6 h
post infection.
Group 2: Mice infected with K. pneumoniae B5055,
administered gentamicin (1.5 mg/kg) intraperitoneally,
6 h post infection.
Group 3: Mice infected with K. pneumoniae B5055,
administered bacterial depolymerase (50 μg), intraperito-
neally, 6 h post infection.
Group 4: Mice infected with K. pneumoniae B5055,
administered bacterial depolymerase (50 μg) and genta-
micin (1.5 mg/kg), intraperitoneally, 6 h post infection.
In each group, blood was taken from mice by retro-
orbital puncture and lungs, liver, kidney, spleen were
removed aseptically, 24 h post infection. Estimation of
bacterial load and pro and anti-inflammatory cytokine
was carried out in tissue homogenates.
Quantification of bacteria
Mice were sacrificed on different days post-infection
by cervical dislocation. Different organs were removed
aseptically and homogenized in 1 ml normal saline.
Serial dilutions of the homogenized tissues were made
and plated on nutrient agar plates. Plates were incubated
at 37°C for 24 h and bacterial counts determined.
Estimation of cytokine levels
Assay for Tumor necrosis factor a (TNF-a), Interleukin-
1 (IL-1), Interleukin-10 (IL-10) was performed by ELISA
using commercially available cytokine kits (Peprotech).
Lungs, liver, kidney, spleen were homogenized in 1 ml
lysis buffer containing 0.5% Triton X 100, 150 mM NaCl,
15 mM Tris, 1 mM CaCl2 and 1 mM MgCl2 (pH 7.4).
Homogenates were centrifuged at 400 g for 10 min and
supernatants were used for estimation of cytokine levels.
Appropriate antigen-affinity purified anti-mouse antibody
pairs, detection reagents (TMB, BD biosciences) and
mouse recombinant cytokines obtained from Peprotech
were used as standards (capture antibodies: rabbit anti-
mouse IL-1ß/IL-10/TNFa; detection antibodies: biotinyl-
ated rabbit anti-mouse IL-1ß/IL-10/TNFa). Absorbance
was measured at 450 nm and results were expressed as
pg/ml of cytokines released. All assays were performed in
triplicates and performed thrice.
Histopathological examination
Lungs were removed aseptically, immersed in 10% forma-
lin fixative and processed for histological examination. The
lung tissue was embedded in paraffin wax and cut into 4–
6 μm thick sections using a microtome. The sections were
stained with haematoxylin and eosin and assessed for
neutrophil infiltration and inflammatory changes.
Generation of antisera
For raising antisera against bacterial depolymerase, 10
Balb/c mice were injected sub-cutaneously on day 0 with
50 μg protein emulsified in CFA (Sigma Aldrich). It was
followed by subcutaneous injection with booster doses
on days 7, 14 and 21 [50 μg protein emulsified in IFA
(Sigma Aldrich)]. Thereafter, mice were bled through
retro-orbital puncture on 10th, 17th and 28th day and
blood serum was collected. Antibody titer was deter-
mined in serum samples using 1:25,000 dilution of goat
anti-mouse HRP conjugate (Bangalore genei) as the sec-
ondary antibody in an enzyme linked immunosorbent
assay. Antibody titer was defined as the reciprocal of
dilution that gave an absorbance of 1.0 at 450 nm after a
30-min reaction with the chromogenic substrate (TMB).
Enzyme efficacy in vivo in presence of antisera
Mice were divided into the following 3 groups with each
group comprising of 10 animals:
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Group 1: Naïve control mice challenged intranasally
with 104 CFU of K. pneumoniae B5055 in a volume of
50 μl followed by treatment with normal saline (0.1 ml/i.p),
24 h post infection.
Group 2: Naïve control mice challenged intranasally
with 104 CFU of K. pneumoniae B5055 in a volume of
50 μl followed by treatment with bacterial depolymerase
(50 μg, i.p), 24 h post infection.
Group 3: Immunized mice (with antibodies against
depolymerase) challenged intranasally with 104 CFU of
K. pneumoniae B5055 in a volume of 50 μl followed by
treatment with bacterial depolymerase (50 μg, i.p), 24 h
post infection.
Bacterial count was determined on the peak day (day 3)
in lungs homogenates of mice belonging to the three
groups and Log10CFU/ml was calculated.
Enzyme activity following incubation with antisera
Bacterial depolymerase was preincubated at 37°C for
60 min with sera obtained from naïve and immunized
mice (antibody titer: 1000) (sera was heated at 56°C for
30 min to inactivate complement before use). Following
this, log phase K. pneumoniae (108 CFU/ml) were treated
with these pre-incubated enzyme samples at 37°C for
60 min. These cells were then washed twice with Hank’s
balanced salt solution (HBSS; 10 mM PBS, pH 7.2, con-
taining 1 mM CaCl2, 0.5 mM MgCl2 and 1 mg/ml glu-
cose) and bacterial number was determined. The bacterial
cells were then opsonized with 10% normal mouse serum
(taken from uninfected mice) for 20 min at 37°C and
bacterial number was confirmed. Thereafter, phagocytosis
of bacteria by macrophages was performed by the method
of Hampton and Winterbourn, [22].
For phagocytosis, the killing efficacy depends on the
MOI i.e. ratio of bacteria and macrophages. In our study,
we tried different MOIs i.e. 1, 10, 100, 1000. But the best
results were obtained with MOI 100. Therefore, it was
selected for this study. Briefly, peritoneal macrophages
(106/ml) were isolated from the peritoneal lavage col-
lected from pathogen free BALB/c mice. Macrophages
were suspended in HBSS containing 10% normal mouse
serum. These were incubated with pretreated opsonized
bacterial cells (108 CFU/ml) at 37°C in 5% CO2. Samples
were withdrawn at appropriate time intervals and an
equal volume of ice-cold PBS was added followed by
centrifugation at 200 g for 5 min. Supernatant was
separated, pellet was washed twice, suspended in PBS with
0.5% triton X solution and incubated at room temperature
for 30 min. Intracellular bacteria recovered after 3 h were
stained with a LIVE-DEAD assay kit (Molecular Probes)
consisting of 30 nM SYTO9 and 15 μM propidium iod-
ide for 15 min in dark. Analysis was done by flow cy-
tometry, using a flow cytometer (BD Biosciences FACS
Canto II) and FACSdiva software. A control tube to
study phagocytic killing of bacterial cells not treated
with depolymerase was also put up simultaneously.
Statistical analysis
Results were analysed statistically by applying one-way
ANOVA (Microsoft Excel 2007) for comparing various
parameters in treated and untreated control mice. Differ-
ences were considered statistically significant if P-value
was less than 0.01.
Results
Effect of intra-peritoneal administration of bacterial
depolymerase on progression of compartmentalized lung
infection
Intranasal instillation of bacteria in mice resulted in bac-
terial load of 4.2 logs, 24 h post infection (Figure 1, day 1).
It was similar to the intranasal dose administered to mice.
Thereafter, multiplication of bacteria in lungs resulted in a
peak in bacterial count on day 3 (8.849 ± 1.321) followed
by subsequent decrease (Figure 1). Intraperitoneal injec-
tion of gentamicin daily (initiated 24 h post infection) was
not effective in this model of experimental pneumonia
as bacterial counts were similar to that observed in un-
treated infected animals throughout the course of infec-
tion. When bacterial depolymerase was injected 24 h
post infection, although bacteria were present in the
lung tissue throughout the course of infection (Figure 1)
but, an average reduction of ~2 logs (P < 0.01) was
observed. Co-administration of gentamicin along with
bacterial depolymerase resulted in significant reduction
(P < 0.01) in average bacterial count (~3.4 logs) in com-
parison to the untreated or gentamicin treated animals.
Effect of intra-peritoneal administration of bacterial
depolymerase on systemic spread of bacteria
Intraperitoneal administration of 102 CFU/0.1 ml of K.
pneumoniae in mice led to bacterial colonization of
liver(s) (6.045 ± 0.325), lungs (5.778 ± 0.314), kidney(s)
(6.491 ± 0.415), spleen(s) (6.934 ± 0.512) and bacteremia
(6.011 ± 0.624) within 24 h (Figure 2). Owing to a
massive spread of bacteria via systemic circulation, ad-
ministration of gentamicin 6 h later did not provide any
significant protection (P > 0.01). In contrast, intraperito-
neal administration of a single 50 μg dose of bacterial
depolymerase, 6 h post infection resulted in significant re-
ductions (P < 0.01) of ~2.7 logs, ~1.5 logs, ~2.5 logs, ~ 2.94
logs and ~3.9 logs in bacterial counts in lungs, liver(s),
kidney(s), spleen(s) and blood respectively (Figure 2).
Simultaneous administration of gentamicin and depoly-
merase, led to almost complete eradication of bacteria,
abolished bacteremia and prevented bacterial dissemin-
ation into various organs.
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Effect of intra-peritoneal administration of bacterial
depolymerase on cytokine expression during
compartmentalized and systemic infection
Acute lung infection with K. pneumoniae accentuated the
release of IL- 1ß, IL-10 and TNFa in untreated animals
(Figure 3). Administration of bacterial depolymerase alone
or in combination with gentamicin resulted in significant
reduction (P < 0.01) in cytokine expression. In comparison
to the uninfected or antibiotic treated animals, a decrease
of ~1.63 fold (IL-1ß), ~1.39 fold (TNFa) and ~2.0 fold
(IL-10) was observed in depolymerase alone treated
mice on day 3. In contrast, a significant reduction (P < 0.01)
of ~3.8 folds (IL-1ß), ~3.97 folds (TNFa) and ~4.9 folds
(IL-10) was seen in depolymerase + gentamicin treated
group (Figure 3a, b, c) on peak day of infection (day 3).
In animals receiving infection intraperitoneally, systemic
spread of infection resulted in marked upregulation in
pro-inflammatory as well as anti-inflammatory cytokine
levels within 24 h. A modest downregulation in levels
of IL-1ß [~1.56 fold (lungs), ~1.37 fold (liver), ~1.52
fold (kidney), ~1.65 fold (spleen)], TNFa [~1.72 fold
(lungs), ~1.56 fold (liver), ~1.75 fold (kidney), ~1.79
Figure 1 Bacterial load (Log10 CFU ml
−1) in the lungs of mice infected via the intranasal route with K. pneumoniae B5055 and treated
with gentamicin (1.5 mg/kg) and/or depolymerase (50 μg). No sample was taken and processed on day 1 in the treated groups. G1, G2, G3,
G4 represent Groups 1, 2, 3, 4. Arrows indicate significant reduction in Log bacterial count between groups on days 2, 3, 5, 7. Error bars represent
standard deviation (S.D) from four independent values.
Figure 2 Bacterial load (Log10 CFU/ml) 24 h post infection in various organs and blood of mice infected via intraperitoneal route with
K. pneumoniae B5055 and treated with gentamicin (1.5 mg/kg) and/or depolymerase (50 μg). G1, G2, G3, G4 represent Groups 1, 2, 3, 4.
Arrows indicate significant reduction in Log bacterial count in all organs and blood from mice belonging to different groups. Error bars represent
standard deviation (S.D) from four independent values.
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fold (spleen)] and IL-10 [~1.46 fold (lungs), ~1.86 fold
(liver), ~1.92 fold (kidney), ~1.75 fold (spleen)] was
observed in the infected, enzyme alone treated animals
(Figure 4a, b, c). In contrast, cytokine levels in the blood
serum samples were significantly reduced (P < 0.01)
by ~2.1 fold (IL-1ß), ~2.43 fold (TNFa and ~3.26 fold
(IL-10) in this group. When depolymerase was used
along with gentamicin, negligible levels of all cytokines
(P < 0.01) were observed in lungs, liver, kidney, spleen
and blood (Figure 4a, b, c).
Histopathological analysis
Massive infiltration of alveoli with neutrophils was ob-
served in lungs of control (Figure 5a) and gentamicin
treated mice (Figure 5b) harvested on the peak day (day 3)
of infection. This indicated the inability of antibiotic to
control the exaggerated state of inflammation in response
to infection. In contrast, depolymerase treated animals
although showed signs of peribronchial inflammation but
had no neutrophil infiltration on day 3 (Figure 5c). Com-
bination treated mice exhibited no signs of inflammation
or neutrophil extravasation (Figure 5d).
Protective efficacy of enzyme in animals previously
exposed to depolymerase
To address the possibility of antibodies against depoly-
merase, neutralizing the protective efficacy offered by
it, hyperimmune serum was raised against the purified
protein in mice. Antibody titer of 1,000 was obtained
against depolymerase. Thereafter, mice with antisera
against depolymerase were challenged intranasally with
104 CFU/50 μl. These were then treated with 50 μg of
depolymerase, 24 h post infection. A count of 8.9
Log10CFU/ml was observed in naïve infected untreated
mice on the peak day (day 3) (Figure 6). In contrast, no
significant difference (P > 0.01) in bacterial count was
observed in immunized treated mice (7 Log10CFU/ml)
and naïve treated mice [(6.6 Log10CFU/ml), not previously
exposed to the enzyme hence with no antisera] (Figure 6).
Furthermore, to confirm the retention of catalytic activ-
ity by bacterial depolymerase after pre-incubation with
antisera raised against it, percentage killing of Klebsiella
by the mouse peritoneal macrophages was estimated. As
observed by flow-cytometry, percentage macrophage kill-
ing of bacteria treated with depolymerase pre-incubated
with antisera was 93.6% (Figure 7c, Q1). Similarly, bacteria
Figure 3 Cytokine levels during acute lung infection: a) IL 1ß b) IL 10 c) TNFa levels (pg/ml) in lungs of mice infected via intranasal
route with K. pneumoniae B5055 and treated with gentamicin (1.5 mg/kg) and/or depolymerase (50 μg). No sample was taken and
processed on day 1 in the treated groups. G1, G2, G3, G4 represent Groups 1, 2, 3, 4. Arrows indicate significant reduction in cytokine levels
between groups on days 2, 3, 5, 7. Error bars represent standard deviation (S.D) from four independent values.
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Figure 4 Cytokine levels during septicemia: a) IL 1ß b) IL 10 c) TNFa levels (pg/ml) 24 h post infection in various organs and blood of
mice infected via intra peritoneal route with K. pneumoniae B5055 and treated with gentamicin (1.5 mg/kg) and/or depolymerase
(50 μg). G1, G2, G3, G4 represent Groups 1, 2, 3, 4. Arrows indicate significant reduction in cytokine levels in all organs and blood from mice
belonging to different groups. Error bars represent standard deviation (S.D) from four independent values.
Figure 5 Lungs of mice infected with K. pneumoniae B5055 and given various treatments intraperitoneally, 24 h post infection (a)
normal saline alone, i.e. control group. (b) gentamicin treated (c) bacterial depolymerase treated (arrows indicate peribronchial inflammation)
(d) bacterial depolymerase and gentamicin treated. (Magnification: 100×).
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which were treated with enzyme pre-incubated with naïve
sera were 95% dead (Figure 7b, Q1). This indicated no sig-
nificant difference in percentage killing of either group of
bacteria by the macrophages after 3 h. In contrast, a sig-
nificantly less percentage macrophage killing was observed
for the untreated bacteria (10%, Figure 7a, Q1).
Discussion
K. pneumoniae accounts for 25-43% of nosocomial pneu-
monias caused by gram negative bacteria. It has a rapid
progressive clinical course often complicated by multilob-
ular involvement and lung abscesses [23] which leaves
little time to institute effective antimicrobial treatment. As
a result, the mortality rates may reach or exceed 50% even
in treated cases [24]. The voluminous capsular layer is in-
volved in adhesion, maintenance, proliferation and devel-
opment of infections by this pathogen [25]. Owing to an
increase in the MDR and NDM-1 strains, the WHO rec-
ommended ampicillin and gentamicin as first line of treat-
ment have proved to be ineffective [26]. Thus a demand
for newer antimicrobials, not affected by resistance mech-
anisms has gained momentum in the last decade [27].
Promising results obtained after using A. punctata
derived depolymerase that lyses K2 capsule of K. pneu-
moniae, thereby improving gentamicin efficacy against
planktonic and biofilm cells of K. pneumoniae (data not
presented) during in vitro studies, prompted us to
evaluate its in vivo therapeutic efficacy. Post infection
administration of single bolus of bacterial depolymerase,
resulted in significant drop (~2 log) in bacterial titers dur-
ing pulmonary infection. Kabha et al., [28] have reported
that Klebsiella with certain CPS types like K21a, contain-
ing mannose-a-2-mannose and rhamnose-a-2/3-rham-
nose sequences are readily recognized by the macrophage
mannose receptor followed by their ingestion and killing.
In contrast, strains with K2 CPS lacking these sequences
Figure 6 Log10CFU/ml on 3
rd day in naïve untreated mice
(Group 1, G1), naïve treated mice (Group 2, G2) and immunized
treated mice (Group 3, G3) challenged with 104 CFU/50 μl
K. pneumoniae B5055.
Figure 7 Phagocytic killing of untreated bacteria (a) bacteria treated with depolymerase pre-incubated with naïve sera (b) bacteria
treated with depolymerase pre-incubated with immune sera (c) as determined through flow cytometry after staining with live-dead
staining kit. (Q4:live cells, Q1:dead cells).
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are not recognized, thus allowing expression of virulence
factors and bacterial proliferation in various organs.
Denudation of K2 capsule by Aeromonas derived enzyme
possibly led to improved uptake and killing of Klebsiella
by alveolar macrophages in lungs.
Studies by Hoffman et al. [29] and Durante-Mangoni
et al. [30] have reported wide use of aminoglycosides to
treat bacterial infections of heart, lung and urinary tract.
Thus, gentamicin was chosen for treating K. pneumoniae
induced acute lung infection. When used at 2.5 mg/kg
or 5 mg/kg post infection, highly significant reduction
(P < 0.001) in bacterial load was observed (data not
presented) indicating its high efficacy at these concentra-
tions. When 1.5 mg/kg gentamicin was administered at
0 h, 6 h, 12 h, 24 h, 48 h, 24 h + 48 h post infection, sig-
nificant reduction in bacterial load was observed in the
first 3 groups on peak day (day 3) (data not presented).
But in the other groups, gentamicin (1.5 mg/kg) alone
could not control the infection. Even when injected daily
till 7th day post infection, no significant protection was
observed. These results indicated that gentamicin was
effective during the initial time when bacteria have not
completely established themselves or started to prolifer-
ate in the lung tissue. Once bacteria colonized, prolifer-
ated in the lung and CPS production was maximal,
gentamicin was no longer effective. Moreover, in clinical
situations also, it takes some time to initiate antibiotic
treatment. Furthermore, Lavender et al. [31], have re-
ported that early stages of K. pneumoniae airway infec-
tions might involve biofilm formation. As suggested by
Kristian et al. [32], biofilm formation inhibits effective-
ness of antibiotic treatment, prevents deposition of host
defense components including C3b and IgG and facili-
tates bacterial communication leading to expression of
virulence determinants. Therefore, A. punctata derived
depolymerase was co-injected 24 h post infection with
gentamicin to check whether it could remove CPS and
render the bacteria susceptible to gentamicin. A reduc-
tion of ≥99% in bacterial titers was seen. This can be at-
tributed to the enzyme mediated dispersal of CPS matrix
leading to improved susceptibility of bacteria towards an
otherwise ineffective gentamicin concentration. Depoly-
merase and gentamicin were comparatively less effective
on the 3rd day because bacterial infection and tissue in-
jury were at its peak and they were unable to tackle it on
their own. Since the infection was confined to lung only,
hence, as the bacterial number decreased by day 4/5, the
agents became more effective. Thus enzyme based ther-
apy helped to overcome the limitations offered by CPS
including slow penetration of aminoglycosides due to
electrostatic interactions with mucus and biofilm matrix.
Disruption of capsular layer also possibly led to im-
proved opsonization and increase in effector function of
leukocytes leading to significant reduction in bacterial
count. Reports by Brown, [33], using antibiotics and
mucolytics in cystic fibrosis patients have also suggested
that the latter provided symptomatic relief by decreasing
mucus viscosity, thereby facilitating bacterial clearance.
Spread of bacteria on intraperitoneal administration led
to bacteremia and colonization of liver, kidney, spleen and
lungs. After intraperitoneal administration, the enzyme
gained quick access to these organs via systemic circula-
tion and through capsule removal facilitated bacterial
clearance by mononuclear phagocytic system operating in
these organs. Merino et al. [34] suggested that during
planktonic growth, K2 capsule of Klebsiella causes com-
plement activation, but activated complement compo-
nents bind far from cell membrane hence, no cell lysis
occurs. Highly significant reduction of bacterial count in
blood on treatment of mice with enzyme can be attributed
to capsule removal which facilitated deposition of comple-
ment components resulting in cell death. Decapsulating
enzymes like endosialidase against E. coli K1 and poly-
glutamic acid depolymerase against B. anthracis have
been shown to prevent the spread of infections by these
bacteria in experimental animals by enhancing their
killing by complement, neutrophils and macrophages
[35-39]. Moreover, reports showing synergy between
enzyme and antibiotic as observed in this study, have
also appeared previously in Gram positive infections
caused by Staphylococcus and Pneumococcus [40,41].
During acute lung infection, bacterial components (CPS
and LPS), macrophage and neutrophil mediators (oxygen
radicals, proteolytic enzymes) and complement compo-
nents induce an inflammatory response. Thus, in the
present study significant increase was observed in levels of
pro-inflammatory as well as anti-inflammatory cytokines
during compartmentalized pneumonia. Witzenrath et al.
[42] and Zelmer et al. [43] have reported reduction in
cytokine expression after treatment of Streptococcus pneu-
moniae infection with lytic enzyme (Cpl-1) and E. coli K1
infection with endosialidase (endoE). Similarly, in our
study significant reduction in cytokine expression was
observed in treated animals. It protected mice from
pathogen induced damage and helped in clearance of
invading bacteria. In enzyme treated animals, during
systemic infection, reduction in cytokine expression
was highly significant, in comparison to that observed
during compartmentalized pneumonia. This indicates
that during respiratory infection, enzyme although in-
terrupts the course of infection, but does not completely
diminish, local tissue response to bacterial invasion. This
might be due to extensive proliferation of the pathogen on
mucosal layer of respiratory tract in biofilm mode contrary
to the presence of planktonic bacteria during systemic
spread. Histopathological examination of lung tissue of in-
fected, untreated animals showed well-developed pneumo-
nia with neutrophil infiltration, abscess formation and
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destruction of alveoli as previously described in our la-
boratory [21]. In contrast, lung tissue of mice treated with
enzyme alone showed signs of peribronchial inflammation
but lung alveoli were completely devoid of neutrophils.
On the other hand, no signs of inflammation and neutro-
phil extravasation was observed in mice treated with
enzyme and gentamicin. Thus it could be concluded that,
enzyme mediated capsule removal did not allow high
bacterial density to be reached, reduced the residence time
of bacteria in mice and sensitized decapsulated bacteria to
gentamicin and components of the immune system.
Since, proteins are immunogenic when delivered sys-
temically, therefore the issue of neutralizing antibodies
interfering with activity of depolymerase after its in vivo
administration was addressed. Inspite of the presence of
antibodies, the ‘enzybiotic’ was equally active in immu-
nized and naïve mice. Moreover, pre-incubation of en-
zyme with its antisera did not hinder the overall bacterial
killing by immune cells. This might be due to presence of
antibodies directed against epitopes that do not contribute
to therapeutic potential of protein or due to a higher bind-
ing affinity of the enzyme for its substrate in comparison
to the antibody’s affinity for enzyme [44].
Conclusion
Conventional antibiotic therapy during gram negative in-
fections generally involves treatment with broad spectrum
antibiotics especially combination of aminoglycoside and
third-generation cephalosporins [45]. But, poor antibiotic
efficacy, emergence of resistant variants and side effects
limit their use in vivo. In contrast, enzymes do not allow
development of resistance, improve antimicrobial efficacy
and have no untoward effects. Reassuring results obtained
after in vivo administration of bacterial depolymerase,
warrant its further examination before including this strat-
egy in the routine treatment regime. With, protein engin-
eering, domain swapping and gene shuffling one can even
evolve a better enzyme for controlling bacterial pathogens
in clinical settings.
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